Here's what we'll cover
Here's what we'll cover
You may not think much about who designs the commercials for your medication. But when one of the world's largest advertising holding companies wins the U.S. media account for the maker of Ozempic and Wegovy, it's worth pausing to understand what that really means for you as a patient.
Omnicom Group, a global advertising powerhouse, has taken over U.S. media planning and buying responsibilities for Novo Nordisk. This is a significant shift in how one of the most talked-about drug companies in recent history will reach American consumers and healthcare providers.
What Omnicom Actually Won and Why It Matters
"Media account" might sound like inside-baseball advertising terminology. In plain terms, it means Omnicom now controls where and how Novo Nordisk spends its U.S. advertising dollars. That includes TV commercials, digital ads, search placements, social media campaigns, and more.
Novo Nordisk has been one of the biggest pharmaceutical advertisers in the United States over the past several years. Semaglutide, the active ingredient in both Ozempic and Wegovy, has become a household name partly because of consistent, high-profile marketing campaigns.
When a company moves its media account to a new agency, it typically signals one of three things: a desire for a fresh creative direction, dissatisfaction with current results, or an ambition to scale spending significantly. For a brand at Novo Nordisk's level, it's likely some combination of all three.
How Drug Advertising Affects the GLP-1 Market
Pharmaceutical advertising in the U.S. operates under FDA guidelines, but it's still a massive, competitive industry. Novo Nordisk competes directly with Eli Lilly, the maker of Mounjaro and Zepbound, for market share in the GLP-1 space.
More advertising spend can do a few things for patients, both positive and neutral.
It Can Increase Awareness
Broader campaigns can bring more people into conversations with their doctors about GLP-1 medications. If you've been on the fence about asking your provider whether semaglutide or tirzepatide is right for you, seeing more ads may prompt that conversation.
It Can Shape Public Perception
Advertising is designed to influence. As Novo Nordisk invests more heavily in media, the framing of obesity as a chronic disease requiring medical treatment will likely intensify. That's actually a medically accurate framing, but it's worth knowing that the message is also commercially motivated.
It Does Not Lower Your Price
This is the most important point. Advertising budgets are expenses that pharmaceutical companies absorb, but they do not result in lower out-of-pocket costs for patients. In fact, high marketing spend is often cited as one factor contributing to elevated drug pricing in the U.S. More commercials do not mean cheaper prescriptions.
What Novo Nordisk's Marketing History Tells Us
Novo Nordisk has been aggressive in promoting both Ozempic and Wegovy. Ozempic was originally approved for type 2 diabetes management, using semaglutide to lower blood sugar. Wegovy uses a higher dose of the same molecule and is specifically approved for chronic weight management.
The marketing of Ozempic for weight loss, though technically off-label use when prescribed for that purpose alone, became so widespread that it contributed to serious supply shortages between 2022 and 2024. That shortage affected people with type 2 diabetes who needed the medication first and foremost, while demand surged from people pursuing weight loss.
A more coordinated, agency-led media strategy could mean Novo Nordisk is more intentional about how it positions each product. That distinction between a diabetes drug and a weight management drug matters for insurance coverage, patient eligibility, and cost.
What This Means for Ozempic and Wegovy Costs
Here is the honest picture: a new advertising agency will not change your prescription price. What drives the cost you pay comes down to your insurance plan, Novo Nordisk's own savings programs, compounding pharmacy availability, and whether you qualify for patient assistance.
As of 2025, the list prices for these medications remain high without coverage.
These prices shift based on insurance, manufacturer coupons, and pharmacy choice. The competitive pressure between Novo Nordisk and Eli Lilly has actually been one of the more patient-friendly market dynamics, with Eli Lilly introducing lower-cost vial options for Zepbound specifically to attract self-pay patients.
How to Actually Reduce Your GLP-1 Costs Right Now
Rather than waiting for advertising shifts to trickle down to patients, which they won't, here are concrete steps you can take today.
Check Novo Nordisk's Savings Programs
Novo Nordisk offers a savings card for Ozempic and a similar program for Wegovy. Eligible commercially insured patients may pay as little as $25 per month. Terms and eligibility requirements apply, and these programs exclude Medicare and Medicaid patients.
Explore Compounding Options Carefully
During the FDA shortage period, compounding pharmacies were permitted to produce semaglutide for patients. The FDA has been narrowing those permissions as the shortage resolves. Talk to your provider about whether any compounded options remain legally available to you, and be cautious of unverified online sources.
Compare Providers and Telehealth Platforms
Not all GLP-1 prescribing platforms charge the same rates for consultations, follow-up care, and medication access. Some telehealth providers bundle medication costs into monthly memberships; others charge separately. Comparing your options through a resource like Best Providers can make a real difference in your total monthly spend.
Use a Coupon
Manufacturer and third-party coupons can reduce costs at the pharmacy counter. Checking GLP-1 Coupons before each refill is a simple habit that can save you hundreds of dollars annually.
Questions to Ask Your Doctor When Marketing Gets Loud
When pharmaceutical advertising intensifies, patients sometimes feel pressure to switch medications, escalate doses faster, or try a newer product. Here are a few grounding questions to bring to your next appointment.
- Is the medication I am currently on still the best fit for my health goals and insurance coverage?
- Has anything changed in terms of what is covered under my plan, or what savings programs I qualify for?
- Are there clinical reasons to consider switching between semaglutide and tirzepatide, beyond what I have seen advertised?
- How do I know if I am seeing a benefit from my current GLP-1 medication, and what timeline should I expect?
Your physician is your best filter for separating marketing from medicine. As Novo Nordisk ramps up its media presence under new agency leadership, that filter becomes more valuable than ever.
The Competitive Landscape and What It Could Mean Long-Term
The GLP-1 market is maturing rapidly. New entrants are coming, including oral semaglutide formulations, once-monthly injectables, and competitors from companies like Amgen and Roche. As the market grows more crowded, advertising competition will intensify across all major players.
That competition, over time, can work in patients' favor. When multiple clinically effective options exist and companies compete for prescriptions, pricing pressure tends to build. We saw a version of this with Eli Lilly's Zepbound vial pricing strategy, which undercut Wegovy's self-pay cost significantly.
Novo Nordisk's decision to invest in a major media agency relationship suggests the company sees significant market share at stake. How aggressively they advertise and to what audiences, those decisions will shape public demand, and potentially influence insurance formulary decisions and policy debates around GLP-1 coverage.
No waiting list. No insurance needed.
Frequently Asked Questions
Will Novo Nordisk's new advertising agency lower the price of Ozempic or Wegovy?
No. Advertising agency changes affect marketing strategy, not drug pricing. The cost of Ozempic and Wegovy is determined by Novo Nordisk's pricing decisions, your insurance plan, and available savings programs. To reduce your cost, focus on manufacturer savings cards, coupons, and comparing telehealth providers.
What is Omnicom and why did it win Novo Nordisk's media account?
Omnicom Group is one of the largest global advertising and media holding companies. Winning a pharmaceutical media account of this size means Omnicom will manage where and how Novo Nordisk spends its U.S. advertising budget across TV, digital, search, and social media. Companies switch agencies to refresh strategy, improve results, or scale their marketing efforts.
How does pharmaceutical advertising affect GLP-1 patients?
Heavy advertising can increase public awareness and prompt more people to ask their doctors about GLP-1 medications. However, it can also inflate demand in ways that affect supply, as happened during the 2022-2024 semaglutide shortage. Advertising shapes perception but does not change clinical eligibility or drug costs.
Is Ozempic approved for weight loss, or just diabetes?
Ozempic (semaglutide) is FDA-approved specifically for type 2 diabetes management. Wegovy, which contains a higher dose of the same active ingredient semaglutide, is FDA-approved for chronic weight management. Using Ozempic for weight loss is considered off-label use, though it is commonly prescribed that way.
How does Novo Nordisk compete with Eli Lilly in the GLP-1 market?
Novo Nordisk sells semaglutide-based medications (Ozempic and Wegovy), while Eli Lilly sells tirzepatide-based medications (Mounjaro and Zepbound). Both companies compete aggressively for prescriptions, insurance formulary placements, and patient awareness. Eli Lilly introduced lower-cost Zepbound vials for self-pay patients, putting pricing pressure on Novo Nordisk.
What savings programs does Novo Nordisk offer for Ozempic and Wegovy?
Novo Nordisk offers savings cards for both Ozempic and Wegovy that may allow eligible commercially insured patients to pay as little as $25 per month. These programs are not available to patients on Medicare or Medicaid. Eligibility requirements vary, so check NovoCare, Novo Nordisk's patient assistance program, for current terms.
The Bottom Line for GLP-1 Patients
A headline about advertising agencies can feel distant from your daily experience of managing weight or blood sugar with a GLP-1 medication. But the business decisions behind these drugs, who markets them, how aggressively, and to whom, do eventually shape the world you navigate as a patient.
More Novo Nordisk advertising may mean more people in your doctor's waiting room asking about semaglutide. It may mean stronger brand recognition that influences what your insurer chooses to cover. And it may mean a louder media environment where separating clinical fact from promotional messaging requires more effort.
The most useful thing you can do is stay grounded in practical information. Know what your medication actually costs and what you can reduce it to with available tools. Understand the difference between Ozempic and Wegovy, and between semaglutide and tirzepatide, so that advertising does not blur those lines for you. Ask your provider direct questions at every appointment.
The GLP-1 market is moving fast, driven by genuine science and significant commercial interest at the same time. Both of those things are true. Staying informed helps you benefit from the first while being appropriately skeptical of the second.
If you are currently comparing GLP-1 medications or looking for the most affordable path to treatment, GLP-1.com has practical tools to help. Check our Best Providers comparison to find a telehealth platform that fits your budget, browse current GLP-1 Coupons before your next refill, or explore the full profiles of Ozempic, Wegovy, and Mounjaro to understand your options. As always, consult your physician before making any changes to your medication plan.